BRPI0410273A - métodos de tratamento de aterosclerose e de aumento dos nìveis de hdl no soro em um paciente humano em necessidade de tal tratamento, e, composição farmacêutica - Google Patents

métodos de tratamento de aterosclerose e de aumento dos nìveis de hdl no soro em um paciente humano em necessidade de tal tratamento, e, composição farmacêutica

Info

Publication number
BRPI0410273A
BRPI0410273A BRPI0410273-8A BRPI0410273A BRPI0410273A BR PI0410273 A BRPI0410273 A BR PI0410273A BR PI0410273 A BRPI0410273 A BR PI0410273A BR PI0410273 A BRPI0410273 A BR PI0410273A
Authority
BR
Brazil
Prior art keywords
treatment
methods
pharmaceutical composition
human patient
hdl levels
Prior art date
Application number
BRPI0410273-8A
Other languages
English (en)
Inventor
Kang Cheng
M Gerard Waters
Kathleen M Metters
Gary O'neill
Original Assignee
Merck & Co Inc
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410273(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc, Merck Frosst Canada Inc filed Critical Merck & Co Inc
Publication of BRPI0410273A publication Critical patent/BRPI0410273A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"MéTODOS DE TRATAMENTO DE ATEROSCLEROSE E DE AUMENTO DOS NìVEIS DE HDL NO SORO EM UM PACIENTE HUMANO EM NECESSIDADE DE TAL TRATAMENTO, E, COMPOSIçãO FARMACêUTICA". A invenção refere-se a um método de tratamento de aterosclerose em que ácido nicotínico ou outro agonista de receptor de ácido nicotínico é administrado ao paciente em combinação com um antagonista de receptor de DP. O antagonista de receptor de DP é administrado para reduzir, evitar ou eliminar sintoma vasomotor que pode de outra forma ocorrer.
BRPI0410273-8A 2003-05-15 2004-05-13 métodos de tratamento de aterosclerose e de aumento dos nìveis de hdl no soro em um paciente humano em necessidade de tal tratamento, e, composição farmacêutica BRPI0410273A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47066503P 2003-05-15 2003-05-15
PCT/US2004/014980 WO2004103370A1 (en) 2003-05-15 2004-05-13 Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BRPI0410273A true BRPI0410273A (pt) 2006-05-16

Family

ID=33476734

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410273-8A BRPI0410273A (pt) 2003-05-15 2004-05-13 métodos de tratamento de aterosclerose e de aumento dos nìveis de hdl no soro em um paciente humano em necessidade de tal tratamento, e, composição farmacêutica

Country Status (44)

Country Link
US (4) US20040229844A1 (pt)
EP (3) EP1624871B1 (pt)
JP (2) JP4637833B2 (pt)
KR (2) KR100960749B1 (pt)
CN (3) CN101559227B (pt)
AR (1) AR041089A1 (pt)
AU (2) AU2004240597B2 (pt)
BR (1) BRPI0410273A (pt)
CA (1) CA2525772C (pt)
CL (1) CL2004001056A1 (pt)
CO (1) CO5630034A2 (pt)
CR (2) CR8047A (pt)
CY (2) CY1109476T1 (pt)
DE (1) DE602004022036D1 (pt)
DK (2) DK2116244T3 (pt)
DO (1) DOP2004000907A (pt)
EA (2) EA011895B1 (pt)
EC (1) ECSP056156A (pt)
ES (2) ES2392743T3 (pt)
GE (2) GEP20084569B (pt)
GT (1) GT200400098A (pt)
HN (1) HN2004000171A (pt)
HR (2) HRP20090424T1 (pt)
IL (1) IL171962A (pt)
IS (1) IS2708B (pt)
JO (1) JO2564B1 (pt)
MA (1) MA27835A1 (pt)
ME (1) MEP60108A (pt)
MX (1) MXPA05012272A (pt)
MY (1) MY140639A (pt)
NO (1) NO20055957L (pt)
NZ (2) NZ543399A (pt)
PA (1) PA8603201A1 (pt)
PE (1) PE20050552A1 (pt)
PL (2) PL1624871T3 (pt)
PT (2) PT2116244E (pt)
RS (3) RS20120499A1 (pt)
SG (1) SG153667A1 (pt)
SI (2) SI1624871T1 (pt)
TN (1) TNSN05290A1 (pt)
TW (2) TWI334354B (pt)
UA (1) UA89615C2 (pt)
WO (1) WO2004103370A1 (pt)
ZA (1) ZA200508288B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4279561B2 (ja) * 2001-05-23 2009-06-17 メルク フロスト カナダ リミテツド プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体
WO2004083388A2 (en) * 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
LT2801354T (lt) 2004-10-08 2017-06-26 Forward Pharma A/S Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US8165517B2 (en) * 2005-01-19 2012-04-24 The Trustees Of The University Of Pennsylvania Methods for identifying inhibitors of vascular injury
CA2598273A1 (en) * 2005-02-17 2006-08-24 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
AU2006214286A1 (en) * 2005-02-18 2006-08-24 Arena Pharmaceuticals, Inc. Methods and compositions for the treatment of lipid-associated disorders
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610133A2 (pt) * 2005-05-17 2010-06-01 Schering Corp heterociclos como agonistas de receptor de ácido nicotìnico para o tratamento de dislipidemia
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20090258862A1 (en) * 2005-08-29 2009-10-15 Colletti Steven L Niacin receptor agonists, compositions containing such compounds and methods of treatment
AU2006284751A1 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
MX2008008340A (es) * 2005-12-21 2008-09-03 Schering Corp Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3.
US20070142369A1 (en) * 2005-12-21 2007-06-21 Margaret Van Heek Combination of an H3 antagonist/inverse agonist and an appetite suppressant
CN101400682A (zh) * 2006-01-20 2009-04-01 先灵公司 治疗异常脂血症的杂环烟酸受体激动剂
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
US20080070890A1 (en) * 2006-09-15 2008-03-20 Burnett Duane A Spirocyclic Azetidinone Compounds and Methods of Use Thereof
WO2008033464A2 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
CN101528227A (zh) * 2006-09-15 2009-09-09 先灵公司 氮杂环丁酮衍生物及其使用方法
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
CN101559058B (zh) * 2008-04-16 2011-07-20 北京本草天源药物研究院 一种治疗血脂异常的药物组合物
BRPI0912842A8 (pt) * 2008-05-20 2019-01-29 Cerenis Therapeutics Holding composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
WO2010036600A1 (en) * 2008-09-24 2010-04-01 Merck Sharp & Dohme Corp. Pharmaceutical compositions of atorvastatin
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
WO2010079222A1 (en) 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
MX2012010035A (es) 2010-03-16 2012-10-01 Aventis Pharma Inc Pirimidinas sustituidas como antagonistas del receptor de la prostaglandina d2.
RU2012143978A (ru) 2010-03-16 2014-04-27 Авентис Фармасьютикалз Инк. Замещенный пиримидин в качестве антагониста рецептора простагландина d2
ES2991300T3 (es) 2015-02-13 2024-12-03 Inserm Institut Nat De La Sante Et De Larecherche Medicale Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) * 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
WO1979000169A1 (en) 1977-09-30 1979-04-05 Rca Corp Television system scheduler
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US5021447A (en) * 1986-01-23 1991-06-04 Merck Frosst Canada, Inc. Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
PT877750E (pt) 1995-10-31 2002-09-30 Schering Corp 2-azetidinonas substituidas por acucar uteis como agentes hipocolesterolemiantes
AU7472896A (en) 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
WO1997023200A1 (en) 1995-12-22 1997-07-03 Kowa Company, Ltd. Pharmaceutical composition stabilized with a basic agent
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
DK1017390T3 (da) * 1997-07-31 2007-06-11 Kos Life Sciences Inc Coated tablet, der omfatter nikotinsyre eller en forbindelse, der metaboliseres til nikotinsyre, i en form med langvarig frigivelse og en HMG-CoA-reduktaseinhibitor i en form med öjeblikkelig frigivelse
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
AU752059B2 (en) * 1997-10-27 2002-09-05 Dr. Reddy's Laboratories Limited Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
HK1039487B (en) 1998-12-07 2005-08-12 Merck Sharp & Dohme Corp. Process for the synthesis of azetidinones
DE69911058T2 (de) 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
ATE549412T1 (de) 1999-04-05 2012-03-15 Schering Corp Stereoselektive mikrobielle reduktion für die herstellung von 1-(4-fluorophenyl)-3(r)- 3(s)- hydroxy-3-(4-fluorophenyl)propyl) -4(s)-(4-hhydroxyphenyl)-2-azetidinon
WO2000063703A1 (en) 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
HUP0301493A2 (hu) 2000-03-09 2003-08-28 Ono Pharmaceutical Co., Ltd. Indolszármazékok, eljárás előállításukra és alkalmazásuk
US20010047027A1 (en) * 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
JP2002008186A (ja) * 2000-06-23 2002-01-11 Mitsubishi Heavy Ind Ltd 車種識別装置
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP3889563B2 (ja) * 2000-09-13 2007-03-07 三洋電機株式会社 映像信号処理回路
AU2002242910A1 (en) 2001-04-11 2002-10-28 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
JP4279561B2 (ja) 2001-05-23 2009-06-17 メルク フロスト カナダ リミテツド プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体
KR20040044856A (ko) 2001-09-07 2004-05-31 오노 야꾸힝 고교 가부시키가이샤 인돌 유도체 화합물
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
ATE516277T1 (de) 2002-03-19 2011-07-15 Ono Pharmaceutical Co Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten
CN100402026C (zh) * 2002-06-03 2008-07-16 诺瓦提斯公司 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4129960B2 (ja) * 2005-07-01 2008-08-06 タキゲン製造株式会社 ステー

Also Published As

Publication number Publication date
CY1109476T1 (el) 2014-08-13
PT2116244E (pt) 2012-11-02
IL171962A (en) 2012-06-28
TWI334354B (en) 2010-12-11
ES2392743T3 (es) 2012-12-13
CN100441184C (zh) 2008-12-10
DOP2004000907A (es) 2004-11-30
NZ572515A (en) 2010-07-30
EA200501817A1 (ru) 2006-06-30
RS20120498A1 (sr) 2013-08-30
CL2004001056A1 (es) 2005-03-28
PL1624871T3 (pl) 2009-12-31
EP2116244B1 (en) 2012-08-08
NO20055957L (no) 2006-02-14
CN1787819A (zh) 2006-06-14
SI2116244T1 (sl) 2012-12-31
AR041089A1 (es) 2005-05-04
EP1624871B1 (en) 2009-07-15
JP4637833B2 (ja) 2011-02-23
US20040229844A1 (en) 2004-11-18
AU2004240597B2 (en) 2011-01-06
JP2010077151A (ja) 2010-04-08
DK1624871T3 (da) 2009-11-16
KR100806008B1 (ko) 2008-02-26
SG153667A1 (en) 2009-07-29
GT200400098A (es) 2005-03-03
PT1624871E (pt) 2009-09-07
IS2708B (is) 2011-01-15
TW200803844A (en) 2008-01-16
RS52731B (sr) 2013-08-30
HN2004000171A (es) 2011-07-11
EA009744B1 (ru) 2008-04-28
DE602004022036D1 (de) 2009-08-27
AU2004240597A1 (en) 2004-12-02
AU2011200986B2 (en) 2012-11-08
CR8047A (es) 2006-07-14
US20100076002A1 (en) 2010-03-25
SI1624871T1 (sl) 2009-12-31
IS8071A (is) 2005-10-13
ECSP056156A (es) 2006-04-19
RS20120499A1 (sr) 2013-08-30
JO2564B1 (en) 2010-11-03
CO5630034A2 (es) 2006-04-28
DK2116244T3 (da) 2012-11-26
PE20050552A1 (es) 2005-08-06
EA011895B1 (ru) 2009-06-30
KR100960749B1 (ko) 2010-06-01
GEP20105025B (en) 2010-06-25
CN101559227A (zh) 2009-10-21
CA2525772C (en) 2011-03-15
CN102526735A (zh) 2012-07-04
ES2328148T3 (es) 2009-11-10
US20110118292A1 (en) 2011-05-19
IL171962A0 (en) 2006-04-10
ZA200508288B (en) 2008-08-27
JP2006526030A (ja) 2006-11-16
EP2286816A1 (en) 2011-02-23
GEP20084569B (en) 2008-12-25
EP1624871A1 (en) 2006-02-15
EA200702674A1 (ru) 2008-04-28
CR9808A (es) 2008-07-29
PL2116244T3 (pl) 2013-01-31
HRP20090424T1 (en) 2009-09-30
CN101559227B (zh) 2012-03-21
MA27835A1 (fr) 2006-04-03
TW200503757A (en) 2005-02-01
MXPA05012272A (es) 2006-05-19
HK1092722A1 (zh) 2007-02-16
TNSN05290A1 (en) 2007-07-10
HRP20120818T1 (hr) 2012-11-30
CA2525772A1 (en) 2004-12-02
TWI341199B (en) 2011-05-01
CY1113342T1 (el) 2016-06-22
PA8603201A1 (es) 2005-02-04
AU2011200986A1 (en) 2011-03-31
KR20080003470A (ko) 2008-01-07
EP2116244A1 (en) 2009-11-11
UA89615C2 (ru) 2010-02-25
MY140639A (en) 2010-01-15
WO2004103370A1 (en) 2004-12-02
RS20050777A (sr) 2008-04-04
KR20060012617A (ko) 2006-02-08
MEP60108A (en) 2011-05-10
US20090233977A1 (en) 2009-09-17
NZ543399A (en) 2009-02-28

Similar Documents

Publication Publication Date Title
BRPI0410273A (pt) métodos de tratamento de aterosclerose e de aumento dos nìveis de hdl no soro em um paciente humano em necessidade de tal tratamento, e, composição farmacêutica
BR0212019A (pt) Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
CY1108201T1 (el) Συσκευες διαδερματικης απελευθερωσης οπιοειδους που ειναι ανθεκτικες στην παραβιαση
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
EA200800007A1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
BR0110420A (pt) Agonistas muscarìnicos
BR9812342A (pt) Analgésica, método de tratar efetivamente a dor em humanos ou outros mamìferos, método para reduzir uma quantidade de opióide requerida para tratamento de pacientes afetados por dor e método para reduzir uma quantidade inibidor cox-2 requerida para tratamento de pacientes afetados por dor
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
BRPI0406749A (pt) Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica
BRPI0418384A (pt) composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
US9205081B2 (en) Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
WO2004006912A3 (en) Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
Bal Kucuk et al. Pharmacotherapeutic agents used in temporomandibular disorders
EP1488807A4 (en) MEANS FOR THE TREATMENT OF SEXUAL-HORMONE-RELATED DISEASES
BRPI0408944A (pt) método para fornecer um benefìcio de redução de esteróide com um inibidor de ciclooxigenase-2 e composições com este
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
BR0308515A (pt) Combinação de um antagonista de receptor de aldosterona com ácido nicotìnico ou um derivado de ácido nicotìnico
Pagnotto et al. Multimodal pain management with peripheral nerve blocks for total knee arthroplasty
BR0111900A (pt) Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK FROSST CANADA AND CO (CA) , MERCK SHARP AND

Free format text: NOME ALTERADO DE: MERCK AND CO., INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERCK FROSST CANADA AND CO (CA) , SCHERING CORPORA

B25D Requested change of name of applicant approved

Owner name: MERCK FROSST CANADA AND CO (CA) , MERCK SHARP AND

B25G Requested change of headquarter approved

Owner name: MERCK FROSST CANADA AND CO (CA) , MERCK SHARP AND

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015.